Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumours
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2016 Planned number of patients changed from 60 to 41.